David A Scott: Data curation
And [being a] compounding pharmacy is not a license to create unapproved new drugs. Nonprofit research and education organization the Center for Medicine in the Public Interest recommended in a July 2025 report that the FDA increase enforcement against companies doing this
Mnch, C
Liu dng: Trong 2 thng u, mi ngy bn ung 3 ln mi ln ung 2 vin
#AstraZeneca #GLP1 #Obesity #Type2Diabetes #ClinicalTrials #CardiometabolicHealth #PharmaInnovation Source: SPER Market ResearchViginovix To view or add a comment, sign in Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in overweight and obesity will be presented at the 2026 American Diabetes Association (ADA) Scientific Sessions, to be held from June 5 to 8, 2026, in New Orleans, Louisiana, USA
Is Semaglutide Safe Long-Term
